10 active not recruiting, 10 completed, 6 recruiting, 3 not yet recruiting. 14 Phase 1, 12 Phase 3, 3 Phase 2.
By phase and status
Follow Maridebart cafraglutide: new trials by email Literature Review of Maridebart cafraglutide trials Research Report on Maridebart cafraglutide
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix .
Trial Phase Status Sponsor Enrollment Start Updated
Comparing the Extent to Which Maridebart Cafraglutide is Made Available in the Body of Participants Living With Overweight or Obesity After Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) Maridebart cafraglutide - Obesity, Overweight Phase 1 Recruiting 180 2026-11-13 2026-11-02 Comparing the Extent to Which Maridebart Cafraglutide (AMG 133) is Made Available in the Body When Administered Using Two Subcutaneous Presentations After Multiple Doses Maridebart cafraglutide - Obesity, Overweight Phase 1 Not yet recruiting 356 2026-11-09 2026-11-06 Home Self-administration of Maridebart Cafraglutide With Autoinjector in Adults Living With Obesity or Overweight Maridebart cafraglutide, Autoinjector - Obesity, Overweight Phase 3 Not yet recruiting 230 2026-10-28 2026-10-13 Maridebart Cafraglutide Versus Semaglutide in Participants With Type 2 Diabetes Maridebart cafraglutide, Semaglutide - Diabetes Mellitus, Type 2 Phase 3 Recruiting 1300 2026-10-16 2026-11-05 Comparing the Extent to Which Two Maridebart Cafraglutide Drug Products Are Made Available in the Body After a Single Subcutaneous Dose Maridebart Cafraglutide - Overweight, Obesity Phase 1 Not yet recruiting 340 2026-10-12 2026-09-22 Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-2-EXTENSION) Maridebart Cafraglutide, Placebo - Obesity, Overweight Phase 3 Recruiting 950 2026-07-29 2026-10-05 Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION) Maridebart cafraglutide, Placebo - Obesity, Overweight Phase 3 Recruiting 3200 2026-07-23 2026-10-05 Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH) Maridebart Cafraglutide - Obesity or Overweight Phase 3 Recruiting 300 2026-05-11 2026-11-06 Effect of Maridebart Cafraglutide on How Oral Contraceptives Are Absorbed and Processed in the Body in Postmenopausal Female Participants Living With Overweight or Obesity COC, Maridebart Cafraglutide - Overweight, Obesity Phase 1 Active not recruiting 49 2026-04-09 2026-07-20 A Trial to Evaluate Efficacy and Safety of Maridebart Cafraglutide in Adults Living With Elevated Liver Fat and Obesity or Overweight Maridebart cafraglutide, Placebo - Overweight or Obesity and Elevated Liver Fat Phase 2 Active not recruiting 180 2026-03-05 2026-09-28 Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea on Positive Airway Pressure Therapy Maridebart cafraglutide, Placebo - Obesity, Obstructive Sleep Apnea Phase 3 Active not recruiting 250 2025-12-19 2026-10-06 A Trial to Compare the Extent to Which Maridebart Cafraglutide (AMG 133) is Made Available in the Body When Administered Using Two Subcutaneous Presentations Maridebart Cafraglutide - Overweight and Obesity Phase 1 Completed 349 2025-12-15 2026-08-07 Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea Not on Positive Airway Pressure (PAP) Therapy Maridebart cafraglutide, Placebo - Obstructive Sleep Apnea Phase 3 Active not recruiting 250 2025-11-25 2026-09-29 Effect of Maridebart Cafraglutide on the Heart's Electrical Activity Maridebart Cafraglutide, Moxifloxacin, Placebo for Maridebart Cafraglutide - Overweight, Obesity Phase 1 Completed 81 2025-10-22 2026-09-22 Comparing the Extent to Which Maridebart Cafraglutide (AMG 133) is Made Available in the Body When Administered Using Two Subcutaneous (SC) Presentations Maridebart Cafraglutide - Overweight, Obesity Phase 1 Completed 348 2025-10-10 2026-06-17 A Study to Evaluate the Effect of Maridebart Cafraglutide on Insulin Sensitivity and β-cell Function in Participants With Type 2 Diabetes Mellitus Maridebart cafraglutide, Placebo - Type 2 Diabetes Mellitus Phase 1 Active not recruiting 56 2025-08-05 2026-06-12 Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity Maridebart Cafraglutide, Placebo - Atherosclerotic Cardiovascular Disease, Overweight Phase 3 Active not recruiting 12800 2025-07-25 2026-10-29 Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity Maridebart cafraglutide, Placebo - Heart Failure With Preserved Ejection Fraction, Heart Failure With Mildly Reduced Ejection Fraction Phase 3 Recruiting 5056 2025-06-25 2026-10-29 Efficacy and Safety of Maridebart Cafraglutide in Adult Participants in Japan Who Have Obesity Disease Maridebart cafraglutide, Placebo - Obesity Disease Phase 3 Active not recruiting 279 2025-06-13 2025-12-17 The Effect of AMG 133 on Gastric Emptying AMG 133, Placebo, Acetaminophen - Overweight or Obesity Phase 1 Completed 57 2025-04-17 2026-02-24
Showing 20 of 29. Sign in to see all of them.
Conditions studied Obesity (26) · Overweight (23) · Diabetes Mellitus, Type 2 (7) · Body Weight (3) · Sleep Apnea, Obstructive (2) · Atherosclerosis (1) · Heart Failure (1) · Insulin Resistance (1)
Sponsors Amgen (29)
Countries United States (25) · Japan (11) · Canada (10) · Poland (8) · Puerto Rico (8) · Australia (7) · Czechia (7) · Germany (7) · Hungary (7) · Spain (7) · South Korea (6) · Hong Kong (5) · Italy (5) · United Kingdom (5) · Argentina (4)
NIH funding 2025 (2) , 2023 (1)